Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAriel Grajales‐CruzKMKizelly Cláudia MatteRGRebecca Gonzalez

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows NGS-MRD negativity predicts improved progression-free and overall survival in multiple myeloma after CAR T-cell therapy, implying a potential for MRD-driven strategies.

Key Points

  • To evaluate the prognostic impact of NGS-MRD status at day 90 post BCMA CAR T-cell therapy in multiple myeloma patients.
  • Retrospective analysis of 171 multiple myeloma patients post standard-of-care BCMA CAR T-cell therapy
  • Assessment of NGS-MRD at 90 days following treatment
  • Statistical analysis using Chi-square test, t-test, Kaplan-Meier method, and Cox regression analyses.
  • 67% of patients were NGS-MRD negative at day 90; showed median progression-free survival of 20 months versus 11 months in MRD positive
  • Overall response rate at 3 months was 98% for MRD negative versus 68% for MRD positive, p<0.0001
  • High-risk cytogenetics and penta-class refractoriness were associated with inferior outcomes.

Cite This Study

Grajales‐Cruz et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d162https://doi.org/10.1182/blood-2025-5846
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  2. 2Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  3. 3Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma2025
  4. 4Impact of minimal residual disease and next generation sequencing discordance in AML following induction with hypomethylating agent + venetoclax.2025
  5. 5What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma2025